Abstract: A universal chirality sensor based on immuno-recognition-driven nanoparticle assembly has been fabricated. The design of smart 10 nm AuNP-antigen and 20 nmAuNP-antibody described for the detection of aflatoxin B1. 10 nm AuNP-antigen and 20 nmAuNP-antibody assemble to symmetric plasmonic nanoparticle dimers, which induced CD signal. The addition of aflatoxin B1 to the chirality sensor resulted in transverse CD signal compared to a blank control as shown by CD measurements. This process also allowed the rapid and facile determination of concentrations of aflatoxin B1 in drinking water (tap water). Good linearity for all calibration curves was obtained, and the limit of detection (LOD) for aflatoxin B1 was 0.02 ng/mL in tap water.

Abstract: Multiple properties of plasmonic assemblies are determined by their geometrical organization. This patent focuses on the formation of Janus structure of the asymmetric assembly structure of the gold nanorods and gold nanoparticles. Chiral structure of gold nanorods and gold nanoparticles can be obtained through the characterization of optical spectra of the Janus structure. And it opens the door for the explanation of the mechanism of the chirality, plays a strong guiding role in the negative refractive material above and has good application prospects.

Abstract: An electrochemical paper-immunosensor and method for detecting aminoglycoside antibiotics is developed in the present invention. Single-walled carbon nanotubes are coated on the common filtration paper by dip-dry cycles. With antibody against neomycin adding to the coating solution, a high sensitive biosensor for specific detection of neomycin is prepared, satisfying to the rigid authority regulations. The sensor is not only sensitive but also rapid, comparing with the classic ELISA method, with LOD of 0.04 ng mL?1 and the whole detection process lasting less than 30 min. Another notable advantage of this invention is the versatility of the sensor, similar method is engaged to prepare the versatile sensor for other aminoglycoside antibiotics, replacement with relevant antibodies.